The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Novel cannabinoid receptors
Open accessAbstract
Cannabinoids have numerous physiological effects. In the years since the molecular identification of the G protein‐coupled receptors CB 1 and CB 2, the ion channel TRPV 1, and their corresponding endogenous ligand systems, many cannabinoid‐evoked actions have been shown conclusively to be mediated by one of these specific receptor targets. However, there remain several examples where these classical cannabinoid receptors do not explain observed pharmacology. Studies using mice genetically deleted for the known receptors have confirmed the existence of additional targets, which have come to be known collectively as non‐CB 1/CB 2 receptors. Despite intense research efforts, the molecular identity of these non‐CB 1/CB 2 receptors remains for the most part unclear. Two orphan G protein‐coupled receptors have recently been implicated as novel cannabinoid receptors; these are GPR119, which has been proposed as a receptor for oleoylethanolamide, and GPR55 which has been proposed as a receptor activated by multiple different cannabinoid ligands. In this review I will present an introduction to non‐CB 1/CB 2 pharmacology, summarize information on GPR55 and GPR119 currently available, and consider their phylogenetic origin and what aspects of non‐CB 1/CB 2 pharmacology, if any, they help explain. British Journal of Pharmacology (2007) 152, 567–575; doi:10.1038/sj.bjp.0707481; published online 1 October 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Lysophosphatidylcholine as a Ligand for the Immunoregulatory Receptor G2A
Kabarowski, J. H. S., Zhu, K., Le, L. Q., Witte, O. N., & Xu, Y. (2001) · Science · doi:10.1126/science.1061781 · Cited by 332
RetractedWitte, O. N., Kabarowski, J. H. S., Xu, Y., Le, L. Q., & Zhu, K. (2005) · Science · doi:10.1126/science.307.5707.206b · Cited by 55
RetractedThe Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · cited 1×
“…which include the bioactive constituents of the marijuana plant Cannabis sativa, as well as endogenous lipids (endocannabinoids) and synthetic compounds with cannabinoid-like activity, interact with specific receptors to cause their effects on target tissues (for review see Pacher et al., 2006).”
BackgroundHirai, H., Tanaka, K., Yoshie, O., Ogawa, K., Kenmotsu, K., Takamori, Y., Ichimasa, M., Sugamura, K., Nakamura, M., Takano, S., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.255 · Cited by 1,099
Fu, J., Gaetani, S., Oveisi, F., Lo Verme, J., Serrano, A., Rodríguez de Fonseca, F., Rosengarth, A., Luecke, H., Di Giacomo, B., Tarzia, G., et al. (2003) · Nature · doi:10.1038/nature01921 · Cited by 1,064
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,064
Control of pain initiation by endogenous cannabinoids
Calignano, A., Rana, G. L., Giuffrida, A., & Piomelli, D. (1998) · Nature · doi:10.1038/28393 · Cited by 1,056
Chinetti, G., Fruchart, J.-C., & Staels, B. (2000) · Inflammation Research · doi:10.1007/s000110050622 · Cited by 954
Lo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., & Piomelli, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006353 · Cited by 882
Cannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728
Cited by
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,529
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M. C., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 614
G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., & Lu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01803-6 · Cited by 491
Cannabinoids and the gut: New developments and emerging concepts
Izzo, A. A., & Sharkey, K. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.005 · Cited by 419
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo
Whyte, L. S., Ryberg, E., Sims, N. A., Ridge, S. A., Mackie, K., Greasley, P. J., Ross, R. A., & Rogers, M. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902743106 · Cited by 330
McHugh, D., Hu, S. S., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J. M., & Bradshaw, H. B. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-44 · Cited by 323
Transdermal cannabidiol reduces inflammation and pain‐related behaviours in a rat model of arthritis
Hammell, D. C., Zhang, L. P., Ma, F., Abshire, S. M., McIlwrath, S. L., Stinchcomb, A. L., & Westlund, K. N. (2016) · European Journal of Pain · doi:10.1002/ejp.818 · Cited by 300
The enigmatic pharmacology of GPR55
Ross, R. A. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.004 · Cited by 296
Brown, J., & Winterstein, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070989 · Cited by 295
Henstridge, C. M., Balenga, N. A. B., Ford, L. A., Ross, R. A., Waldhoer, M., & Irving, A. J. (2009) · The FASEB Journal · doi:10.1096/fj.08-108670 · Cited by 285
Staton, P. C., Hatcher, J. P., Walker, D. J., Morrison, A. D., Shapland, E. M., Hughes, J. P., Chong, E., Mander, P. K., Green, P. J., Billinton, A., et al. (2008) · Pain · doi:10.1016/j.pain.2008.04.006 · Cited by 270
“Given that a number of cannabinoid ligands activate GPR55 [4,37] and the recent finding that GPR55 activation can inhibit potassium current through M-type potassium channels [20], it is possible that GPR55 also has a pro-nociceptive role.”
BackgroundYamashita, A., Hayashi, Y., Nemoto-Sasaki, Y., Ito, M., Oka, S., Tanikawa, T., Waku, K., & Sugiura, T. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2013.10.001 · Cited by 268
Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies
Finn, D. P., Haroutounian, S., Hohmann, A. G., Krane, E., Soliman, N., & Rice, A. S. C. (2021) · Pain · doi:10.1097/j.pain.0000000000002268 · Cited by 254
Moreira, F. A., & Wotjak, C. T. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_16 · Cited by 177
Loría, F., Petrosino, S., Mestre, L., Spagnolo, A., Correa, F., Hernangómez, M., Guaza, C., Di Marzo, V., & Docagne, F. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06377.x · Cited by 109
“two extracellular cannabinoid receptors, termed CB1 and CB2, and several other, still not identified receptors (Brown, 2007), which could include members of the peroxisome proliferator-activated receptor (PPAR) family of intracellular receptors and of the transient receptor potential (TRP) family of channels (De Petro…”
BackgroundBrusberg, M., Arvidsson, S., Kang, D., Larsson, H., Lindström, E., & Martinez, V. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5166-08.2009 · Cited by 88
Cannabinoids: new promising agents in the treatment of neurological diseases.
Giacoppo, S., Mandolino, G., Galuppo, M., Bramanti, P., & Mazzon, E. (2014) · Molecules · doi:10.3390/molecules191118781 · Cited by 79
Metadata
- Authors
- Brown, A. J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-11
- Volume
- 152
- Issue
- 5
- Pages
- 567-575
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1824285398
- Cited by
- 409
- References
- 61
- FWCI
- 25.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.